Patrick Neven
#126,164
Most Influential Person Now
Researcher
Patrick Neven's AcademicInfluence.com Rankings
Patrick Nevencomputer-science Degrees
Computer Science
#5307
World Rank
#5606
Historical Rank
Computational Linguistics
#708
World Rank
#720
Historical Rank
Machine Learning
#1359
World Rank
#1380
Historical Rank
Artificial Intelligence
#1594
World Rank
#1624
Historical Rank
Download Badge
Computer Science
Patrick Neven's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Patrick Neven Influential?
(Suggest an Edit or Addition)Patrick Neven's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Endometrial cancer. (2005) (2344)
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. (2017) (950)
- Association analysis identifies 65 new breast cancer risk loci (2017) (922)
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. (2018) (580)
- Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes (2018) (559)
- Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. (2011) (536)
- Parent-of-origin specific allelic associations among 106 genomic loci for age at menarche (2014) (511)
- Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer (2015) (502)
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. (2014) (459)
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 (2019) (440)
- Genome-wide association studies identify four ER negative–specific breast cancer risk loci (2013) (411)
- Endometrial cancer (2005) (406)
- Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. (2007) (388)
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. (2011) (358)
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. (2019) (354)
- Adjuvant trastuzumab in HER2-positive breast cancer. (2012) (346)
- CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. (2012) (332)
- Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. (2008) (329)
- Large-scale genomic analyses link reproductive ageing to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair (2015) (308)
- Endometriosis and the development of malignant tumours of the pelvis. A review of literature. (2004) (295)
- Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. (2010) (274)
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) (2020) (274)
- Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. (2013) (248)
- Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. (2013) (241)
- Breast cancer in pregnancy: recommendations of an international consensus meeting. (2010) (236)
- Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole (2008) (219)
- Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. (2007) (210)
- Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent (2016) (205)
- Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study (2011) (192)
- Management of borderline ovarian neoplasms. (2007) (192)
- Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. (2011) (192)
- TAMOXIFEN AND THE UTERUS AND ENDOMETRIUM (1989) (185)
- Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer (2005) (180)
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations (2013) (176)
- Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. (2015) (173)
- A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer (2021) (169)
- Effectiveness of postoperative physical therapy for upper-limb impairments after breast cancer treatment: a systematic review. (2015) (162)
- Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors (2013) (159)
- Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. (2016) (157)
- Lasofoxifene in postmenopausal women with osteoporosis. (2010) (156)
- Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. (2008) (152)
- Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial (2016) (150)
- A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer (2018) (149)
- Advances in the treatment of advanced oestrogen-receptor-positive breast cancer (2017) (148)
- Lack of genotoxicity of tamoxifen in human endometrium. (1996) (145)
- Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma (2007) (143)
- Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. (2005) (135)
- Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. (2010) (133)
- Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. (2008) (132)
- A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. (1996) (130)
- Update on triple-negative breast cancer: prognosis and management strategies (2012) (130)
- Breast cancer in pregnancy (2012) (129)
- Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients (2004) (129)
- Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. (2013) (124)
- Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The SOLD Randomized Clinical Trial (2018) (124)
- Sexual functioning in women after mastectomy versus breast conserving therapy for early-stage breast cancer: a prospective controlled study. (2014) (118)
- Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging (2007) (116)
- Endometrial lesions in patients undergoing tamoxifen therapy (1991) (115)
- Port‐site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma (2005) (115)
- Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. (2012) (113)
- Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2014) (112)
- Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2019) (110)
- Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. (2015) (107)
- Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome. (2007) (104)
- Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? (2008) (102)
- Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years (2003) (100)
- Additional Value of PET–CT in Staging of Clinical Stage IIB and III Breast Cancer (2010) (100)
- Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study (2014) (99)
- Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial (2018) (97)
- Effect of manual lymph drainage in addition to guidelines and exercise therapy on arm lymphoedema related to breast cancer: randomised controlled trial (2011) (97)
- Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice. (2013) (96)
- Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial (2013) (92)
- Timing of debulking surgery in advanced ovarian cancer (2008) (91)
- Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. (2012) (90)
- Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. (2016) (90)
- Hysteroscopic follow-up during tamoxifen treatment. (1990) (88)
- The Role of Inhibins B and Antimüllerian Hormone for Diagnosis and Follow-up of Granulosa Cell Tumors (2009) (88)
- Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive (2008) (87)
- Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) (2010) (85)
- Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials (2015) (85)
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. (2021) (84)
- The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formation (2013) (84)
- Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival. (2021) (83)
- Physical activity levels after treatment for breast cancer: one-year follow-up (2010) (83)
- Lifestyle changes and breast cancer prognosis: a review (2009) (81)
- Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review (2016) (81)
- Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. (2018) (80)
- Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. (2018) (79)
- Longitudinal hysteroscopic follow-up during tamoxifen treatment (1998) (78)
- Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy (2017) (77)
- Raloxifene Effect on Frequency of Surgery for Pelvic Floor Relaxation (2001) (76)
- The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial (2009) (76)
- BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. (2016) (76)
- Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? (2009) (75)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
- Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses (2016) (72)
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer (2012) (71)
- Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related (2005) (68)
- Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. (2009) (67)
- Robotic retroperitoneal lower para‐aortic lymphadenectomy in cervical carcinoma: First report on the technique used in 5 patients (2008) (67)
- The costs of breast cancer prior to and following diagnosis (2011) (66)
- Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. (2013) (63)
- Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. (1999) (62)
- Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). (2013) (62)
- Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). (2016) (61)
- Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. (2005) (61)
- Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198 (2007) (60)
- The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. (2009) (60)
- Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) (2012) (60)
- Management of menopausal symptoms in breast cancer patients. (2011) (59)
- The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. (2010) (58)
- Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. (2019) (58)
- A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy (2008) (57)
- Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes (2011) (57)
- Triple negative breast cancer: clinical characteristics in the different histological subtypes. (2013) (57)
- Treatment modalities in endometrial cancer (2007) (55)
- Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. (2013) (54)
- Should tamoxifen users be screened for endometrial lesions? (1998) (54)
- Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer (2016) (54)
- Relationship between age and axillary lymph node involvement in women with breast cancer. (2009) (54)
- Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients (2015) (54)
- Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer† (2015) (52)
- Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. (2005) (52)
- Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. (2010) (52)
- Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. (2002) (51)
- Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. (2015) (51)
- A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. (2013) (51)
- Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study) (2006) (51)
- Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. (2019) (51)
- Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. (2012) (51)
- CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects (2015) (51)
- Measurement of urinary beta core fragment of human chorionic gonadotrophin in women with vulvovaginal malignancy and its prognostic significance. (1995) (50)
- Guidelines for Monitoring Patients Taking Tamoxifen Treatment (2000) (50)
- Sensitive routine liquid chromatography–tandem mass spectrometry method for serum estradiol and estrone without derivatization (2013) (50)
- Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer (2015) (49)
- Tamoxifen and the uterus and endometrium. (1989) (49)
- Effects of tamoxifen on uterus (1994) (49)
- Transition of endometrial stromal sarcoma into high-grade sarcoma. (2006) (47)
- Aromatase inhibitors in the breast cancer clinic: focus on exemestane. (2014) (47)
- PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer. (2013) (46)
- The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars (2019) (46)
- Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. (2013) (45)
- The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. (2014) (45)
- Role of diaphragmatic surgery in 69 patients with ovarian carcinoma (2007) (45)
- Laparoscopic para‐ aortic lymphadenectomy and positron emission tomography scan as staging procedures in patients with cervical carcinoma stage IB2–IIIB (2008) (44)
- Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. (2015) (44)
- Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial (2018) (44)
- Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene (2012) (43)
- Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs (2011) (43)
- Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. (2011) (43)
- Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB) (2019) (43)
- Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1 (2009) (42)
- Prophylactic salpingo‐oophorectomy in 51 women with familial breast–ovarian cancer: importance of fallopian tube dysplasia (2006) (42)
- Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYL (2020) (42)
- Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. (2012) (42)
- Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy (2008) (42)
- The diagnostic problem of endometrial stromal sarcoma: report on six cases. (2003) (42)
- Arm lymphoedema and upper limb impairments in sentinel node-negative breast cancer patients: A one year follow-up study. (2016) (42)
- Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study (2017) (42)
- Biological ageing and frailty markers in breast cancer patients (2015) (42)
- The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. (2007) (41)
- Endometrial safety of hormone replacement therapy: review of literature. (2002) (41)
- Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors (2018) (39)
- Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer. (2010) (39)
- Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance (2016) (39)
- Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer (2014) (39)
- The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters (2016) (39)
- Vaginal estriol–lactobacilli combination and quality of life in endocrine-treated breast cancer (2015) (38)
- A Mathematical Model for Interpretable Clinical Decision Support with Applications in Gynecology (2012) (38)
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial (2022) (38)
- 11q13 is a susceptibility locus for hormone receptor positive breast cancer (2012) (38)
- Body mass index and breast cancer survival: a Mendelian randomization analysis (2017) (38)
- Chemotherapy for recurrent cervical cancer. (2007) (38)
- The management of borderline tumours of the ovary (2006) (37)
- Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. (2015) (37)
- Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab (2018) (36)
- Prevention of breast cancer (1992) (36)
- Symptoms of endocrine treatment and outcome in the BIG 1-98 study (2013) (35)
- The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients (2016) (35)
- Lymphadenectomy in endometrial cancer (2009) (35)
- A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI (2014) (34)
- 2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let) (2007) (34)
- Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer (2015) (34)
- Tamoxifen, screening and new oestrogen receptor modulators. (2001) (34)
- Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. (2019) (33)
- Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21 (2016) (33)
- Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen. (1998) (33)
- Pain characteristics as important contributing factors to upper limb dysfunctions in breast cancer survivors at long term. (2017) (33)
- Multivariate analysis of factors affecting survival in pelvic exenteration (1994) (33)
- Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene‐Environment Interactions (2014) (33)
- Wilms' tumor gene 1 (WT1) in endometrial carcinoma. (2008) (31)
- Quasiclassical theory of disordered multi-channel Majorana quantum wires (2013) (31)
- Usefulness of urodynamic investigations in female incontinence. (1992) (31)
- Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view. (2008) (31)
- Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (31)
- Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. (2020) (30)
- Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients (2011) (30)
- Delivery of adjuvant sequential dose-dense FEC–Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence (2009) (30)
- Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. (2009) (29)
- TRASTUZUMAB TREATMENT OF EARLY STAGE BREAST CANCER IS COST-EFFECTIVE FROM THE PERSPECTIVE OF THE BELGIAN HEALTH CARE AUTHORITIES (2009) (29)
- Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. (2020) (29)
- Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting (2005) (29)
- Tamoxifen and the uterus (1994) (28)
- Neoadjuvant chemotherapy for ovarian cancer. (2005) (28)
- The prognostic significance of urinary beta core fragment in premenopausal women with carcinoma of the cervix. (1994) (28)
- Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. (2011) (28)
- Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors (2015) (28)
- The genetic landscape of 87 ovarian germ cell tumors. (2018) (28)
- Behavior of metastatic breast cancer according to subtype (2020) (27)
- Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy (2018) (27)
- Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. (2014) (26)
- Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers. (2013) (26)
- CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial (2015) (26)
- A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer (2007) (26)
- Tamoxifen and the gynaecologist (1993) (25)
- Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors (2009) (25)
- S1-3: Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST. (2011) (25)
- Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. (2013) (25)
- Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data (2021) (25)
- A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate (2003) (25)
- Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3 (2018) (24)
- BREAST CANCER PREVENTION: LIFESTYLE CHANGES AND CHEMOPREVENTION (2011) (23)
- Plasma Gelatinase Levels in Patients with Primary Breast Cancer in Relation to Axillary Lymph Node Status, Her2/neu Expression and other Clinicopathological Variables (2005) (23)
- Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. (2018) (23)
- Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative study (2008) (23)
- Prospective external validation of the ‘ovarian crescent sign’ as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology (2010) (23)
- Effect of myofascial techniques for treatment of upper limb dysfunctions in breast cancer survivors: randomized controlled trial (2017) (23)
- Inter-rater reliability of shoulder measurements in middle-aged women. (2017) (22)
- Leuven Dose-Dense Paclitaxel/Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma (2009) (22)
- Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. (2020) (22)
- Effects of a mindfulness-based intervention on cancer-related cognitive impairment: Results of a randomized controlled functional magnetic resonance imaging pilot study. (2020) (22)
- Serum, Pleural Effusion, and Ascites CA-125 Levels in Ovarian Cancer and Nonovarian Benign and Malignant Diseases: A Comparative Study (2002) (22)
- Malignant melanoma of the vulva and vagina: a report of 23 cases presenting in a 10-year period (1993) (22)
- Effect of myofascial techniques for treatment of persistent arm pain after breast cancer treatment: randomized controlled trial (2018) (22)
- The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women (2002) (22)
- A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. (2015) (22)
- Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors (2014) (22)
- Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel (2014) (22)
- Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty (2017) (21)
- Lymph node ratio better predicts disease-free survival in node-positive breast cancer than the number of positive lymph nodes. (2009) (21)
- Pharmacology of arthralgia with estrogen deprivation (2011) (21)
- Activity of fulvestrant in HER2-overexpressing advanced breast cancer. (2010) (21)
- Age‐dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients (2019) (21)
- Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients. (2016) (21)
- Age‐related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer (2020) (21)
- Matrix Metalloproteinase Expression Patterns in Luminal A Type Breast Carcinomas (2007) (21)
- A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients. (2008) (20)
- Protocol of a randomised controlled trial regarding the effectiveness of fluoroscopy-guided manual lymph drainage for the treatment of breast cancer-related lymphoedema (EFforT-BCRL trial). (2017) (20)
- Tamoxifen-induced endometrial polyp. (1997) (20)
- The Role of Adjuvant Chemotherapy in Surgical Stages I-II Serous and Clear Cell Carcinomas and Carcinosarcoma of the Endometrium: A Collaborative Study (2010) (20)
- Myofascial techniques have no additional beneficial effects to a standard physical therapy programme for upper limb pain after breast cancer surgery: a randomized controlled trial (2017) (20)
- Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2− advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy (2013) (20)
- Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer (2008) (20)
- Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry (2016) (20)
- Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer (2019) (19)
- Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors (2016) (19)
- Safety of aromatase inhibitor therapy in breast cancer (2015) (19)
- Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age (2007) (19)
- Manual lymph drainage may not have a preventive effect on the development of breast cancer-related lymphoedema in the long term: a randomised trial. (2018) (19)
- No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
- Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies (2021) (18)
- The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers (2021) (18)
- MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy (2017) (18)
- Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study (2020) (18)
- Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. (2020) (18)
- The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancer. (2017) (18)
- Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen (2020) (17)
- Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium. (2015) (17)
- MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer (2019) (17)
- Abstract P5-11-01: The Effect of Zoledronic Acid on Aromatase Inhibitor Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The ZO-FAST Study 5-Year Final Follow-Up (2010) (17)
- The footprint of the ageing stroma in older patients with breast cancer (2017) (17)
- Coping with menopausal symptoms: An internet survey of Belgian postmenopausal women. (2015) (17)
- THE DIAGNOSTIC PROBLEM OF ENDOMETRIAL STROMAL SARCOMA: REPORT ON SIX CASES (2003) (16)
- Does patient education work in breast cancer? Final results from the global CARIATIDE study. (2015) (16)
- Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape (2021) (16)
- Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines (2020) (16)
- P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial. (2011) (16)
- Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. (2014) (16)
- Tamoxifen and endometrial lesions (1993) (16)
- Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer. (2018) (16)
- The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formation (2014) (16)
- Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor (2011) (16)
- ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer (2015) (16)
- Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer (2021) (15)
- Clinical Significance of PIK3CA and ESR1 Mutations in circulating tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib Plus Fulvestrant. (2022) (15)
- Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. (2014) (15)
- Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study) (2018) (15)
- Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer (2016) (15)
- Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. (2019) (15)
- Obesity alters endoxifen plasma levels in young breast cancer patients: A pharmacometric simulation approach. (2020) (15)
- Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data (2014) (15)
- Substantial urinary concentrations of material resembling beta-core fragment of chorionic gonadotropin beta-subunit in mid-menstrual cycle. (1993) (15)
- Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. (2014) (15)
- Reconstruction of the abdominal wall with a latissimus dorsi musculocutaneous flap: a case of a massive abdominal wall metastasis from a cervical cancer requiring palliative resection. (1993) (15)
- Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1. (2005) (15)
- The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. (2002) (15)
- Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy (2019) (15)
- Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users (2009) (14)
- Limited Clinical Benefit from Trastuzumab in Recurrent Endometrial Cancer (2008) (14)
- Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). (2021) (14)
- Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3. (2018) (14)
- Neoadjuvant Weekly Paclitaxel-Carboplatin Is Effective in Stage I–II Cervical Cancer (2017) (14)
- Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer (2013) (14)
- A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis (2008) (14)
- Prevalence of HIV antibody and pregnancy in Tayside, 1984-9: background to screening. (1990) (14)
- Controversies regarding tamoxifen and uterine carcinoma. (1998) (14)
- Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. (2015) (14)
- Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: an analysis of 163 patients. (2011) (14)
- Modulation of endometrial transforming growth factor β (TGFβ) by tamoxifen (2000) (14)
- Abstract PS12-04: Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2- locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection (2021) (14)
- The oestrogen receptor and its selective modulators in gynaecological and breast cancer. (2000) (13)
- Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors (2019) (13)
- Tamoxifen and the uterus. (1998) (13)
- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. (2022) (13)
- Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us? (2008) (13)
- Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer (2006) (13)
- Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer (2008) (13)
- Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results. (2021) (13)
- The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen. (2014) (13)
- A Core Invasiveness Gene Signature Reflects Epithelial-to-Mesenchymal Transition but Not Metastatic Potential in Breast Cancer Cell Lines and Tissue Samples (2014) (13)
- The Role of Diaphragmatic Surgery During Interval Debulking After Neoadjuvant Chemotherapy: an Analysis of 74 Patients With Advanced Epithelial Ovarian Cancer (2010) (13)
- EP-EMA Regimen (Etoposide and Cisplatin With Etoposide, Methotrexate, and Dactinomycin) in a Series of 18 Women With Gestational Trophoblastic Neoplasia (2012) (13)
- Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC). (2014) (13)
- Uterine Effects of Estrogen Plus Progestin Therapy and Raloxifene: Adjudicated Results From the EURALOX Study (2004) (13)
- Value of positron emission tomography of the para-aortic lymph nodes in cervical carcinoma stage IB2-IIIB. (2008) (12)
- A Systematic Review of Estimating Breast Cancer Recurrence at the Population-Level with Administrative Data. (2020) (12)
- A unifying model to predict variable drug response for personalised medicine (2020) (12)
- Prognostic implications of lobular breast cancer histology: new insights from a single hospital cross-sectional study and SEER data. (2014) (12)
- Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass (2012) (12)
- Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant. (2006) (12)
- AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). (2021) (12)
- A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer (2021) (12)
- Tamoxifen and the female genital tract. (1998) (12)
- Abstract PD2-05: Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study (2019) (12)
- The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study. (2013) (12)
- Weekly Paclitaxel-Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma (2012) (12)
- Urinary chorionic gonadotropin subunits and β‐core in nonpregnant women. A study of benign and malignant gynecologic disorders (1993) (12)
- Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy (2019) (12)
- Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer (2016) (11)
- Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity (2020) (11)
- Correlation Between Clinical Assessment and Lymphofluoroscopy in Patients with Breast Cancer-Related Lymphedema: A Study of Concurrent Validity. (2020) (11)
- Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy (1990) (11)
- Extending the Developmental Origins of Health and Disease theory: does paternal diet contribute to breast cancer risk in daughters? (2016) (11)
- Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen‐treated women (2003) (11)
- Treatment of cancer during pregnancy: the need for tailored strategies (2010) (11)
- Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. (2022) (11)
- Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. (2021) (11)
- Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial (2015) (11)
- Identification and characterization of novel associations in the CASP 8 / ALS 2 CR 12 region on chromosome 2 with breast cancer risk (2014) (11)
- Clinicopathological Features of Inflammatory versus Noninflammatory Locally Advanced Nonmetastatic Breast Cancer (2008) (11)
- Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy (2018) (11)
- Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer (2018) (11)
- Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) +/- trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data (2006) (11)
- Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature (2020) (10)
- P105 Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (2005) (10)
- Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers. (2013) (10)
- Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation (2017) (10)
- Abstract P6-18-06: Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials (2019) (10)
- Local levonorgestrel to prevent tamoxifen-related endometrial lesions (2000) (10)
- A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging (2020) (10)
- Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche DTU Orbit (05/11/2017) (2014) (10)
- Need for estradiol assays with a lower functional sensitivity in clinical studies examining postmenopausal women treated with aromatase inhibitors. (2013) (10)
- A mindfulness-based intervention for breast cancer patients with cognitive impairment after chemotherapy: study protocol of a three-group randomized controlled trial (2019) (10)
- Exposure–response analysis of endoxifen serum concentrations in early-breast cancer (2020) (10)
- Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. (2022) (10)
- Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial (2021) (9)
- 29PA NEGATIVE PROGESTERONE RECEPTOR IN LUMINAL HER-2 NEGATIVE BREAST CANCER BY AGE AT DIAGNOSIS: 10 YEARS FOLLOW-UP (2014) (9)
- The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers. (2013) (9)
- Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer (2020) (9)
- Modulation of endometrial transforming growth factor beta (TGFbeta) by tamoxifen. (2000) (9)
- A Real-Life Analysis of Reproductive Outcome after Fertility Preservation in Female Cancer Patients (2017) (9)
- An evaluation tool for myofascial adhesions in patients after breast cancer (MAP-BC evaluation tool): Development and interrater reliability (2017) (9)
- An unusual type of endometrial cancer, related to tamoxifen? (1992) (9)
- Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2 (2016) (9)
- Abstract P3-10-05: Triple Negative Breast Cancer: Clinical Characteristics in the Different Histological Subtypes (2010) (9)
- Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes (2019) (9)
- Drug safety evaluation of exemestane (2011) (9)
- Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients. (2006) (8)
- Does Paclitaxel-Carboplatin Chemotherapy in a Dose-Dense Regimen Enhance Survival of BRCA-Related Ovarian Cancer Patients? (2009) (8)
- Early drain removal improves quality of life and clinical outcomes in patients with breast cancer - Results from a randomised controlled trial. (2018) (8)
- The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer (2021) (8)
- Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma. (2013) (8)
- Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3 (2021) (8)
- BREAST CANCER IN WOMEN: DIAGNOSIS, TREATMENT AND FOLLOW-UP (2013) (8)
- Numb chin syndrome as a sign of mandibular metastasis: A case report (2017) (8)
- LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) (2022) (8)
- Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related. (2006) (8)
- Effectiveness of Botulinum Toxin A for Persistent Upper Limb Pain After Breast Cancer Treatment: A Double-Blinded Randomized Controlled Trial. (2018) (8)
- An evaluation tool for Myofascial Adhesions in Patients after Breast Cancer (MAP-BC evaluation tool): Concurrent, face and content validity (2018) (8)
- Gemcitabine–carboplatin–paclitaxel combination as first‐line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients (2006) (8)
- Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy. (2018) (8)
- Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate-etoposide. (2012) (8)
- The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer. (2007) (8)
- Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes (2020) (7)
- SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC). (2017) (7)
- Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. (2013) (7)
- Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant (2009) (7)
- SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease. (2021) (7)
- II.2 Tamoxifen and benign endometrial lesions (1998) (7)
- In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement. (2008) (7)
- Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a prospective cohort of patients with early-stage breast cancer. (2011) (7)
- The immunocytochemical versus cytosol measurement of the oestrogen receptor in invasive breast cancer tissue. (2000) (7)
- Tamoxifen therapy for patients with breast cancer (2013) (7)
- Postpartum breast cancer behaves differently (2011) (7)
- The validity and reliability of real-time ultrasound estimation of bladder volume in postnatal women (1996) (7)
- Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. (2020) (7)
- Everolimus in acute kidney injury in a patient with breast cancer: a case report (2014) (7)
- Abstract OT2-6-04: Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-) / hormone receptor-positive (HR+) breast cancer: A phase II, randomized, double blind, placebo-controlled (2013) (7)
- The origin of postmenopausal oestrogens. (2002) (7)
- Abstract 4458: Clinical significance ofPIK3CAandESR1mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant (2019) (7)
- Is it safe to treat endometrial carcinoma endoscopically? (2009) (7)
- Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6) (2022) (6)
- BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer. (2013) (6)
- Short-Term Prognostic Index for Breast Cancer: NPI or Lpi (2007) (6)
- Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC) (2019) (6)
- Abstract PD2-08: Gene expression analysis and association with treatment response in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer in the MONALEESA-3 study (2020) (6)
- Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study (2018) (6)
- Reproducibility of lymphoscintigraphic evaluation of the upper limb. (2014) (6)
- Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: an analysis of 208 patients (2002) (6)
- Breast cancer subtype and survival by parity and time since last birth (2018) (6)
- Combined modality adjuvant therapy for high-risk endometrial cancer. (2016) (6)
- Safety of the anti-IGF-1R antibody CP-751,871 in combination with exemestane in patients with advanced breast cancer. (2009) (6)
- How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years? (2014) (6)
- Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2018) (6)
- Reproduction rates after cytotoxic therapy. (2009) (6)
- Evaluation of a breast cancer nomogram to predict ipsilateral breast relapse after breast-conserving therapy. (2016) (6)
- Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast (2022) (6)
- Staging with Unilateral Salpingo-Oophorectomy and Expert Pathological Review Result in No Recurrences in a Series of 81 Intestinal-Type Mucinous Borderline Ovarian Tumors (2017) (6)
- Quality of pathology reporting is crucial for cancer care and registration: a baseline assessment for breast cancers diagnosed in Belgium in 2008. (2015) (6)
- Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2− early breast cancer (2021) (6)
- Risk group detection and survival function estimation for interval coded survival methods (2013) (6)
- Other selective oestrogen receptor modulators (SERMs) in development. (2000) (5)
- Association between CYP2D6 polymorphisms and breast cancer outcomes. (2010) (5)
- Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial (2021) (5)
- Ribociclib plus fulvestrant in the treatment of breast cancer (2020) (5)
- Does the Stellate Ganglion Block Reduce Severe Hot Flushes and Sleep Disturbances in Breast Cancer Patients (2009) (5)
- I.3 An epigenetic mechanism for tamoxifen-associated uterine carcinogenesis? (1998) (5)
- Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium. (2014) (5)
- Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (2018) (5)
- Abstract P6-21-01: Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results (2019) (5)
- Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris (2019) (5)
- Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (2019) (5)
- Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): final analysis. (2009) (5)
- BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. (2012) (5)
- Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe (2015) (5)
- Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria. (2021) (5)
- The added value of geriatric assessment in evaluating a patient's Health-Related Quality-of-Life: A study in ≥70-year-old early-stage invasive breast cancer patients. (2020) (5)
- Endometrial changes in patients on tamoxifen. (1995) (5)
- Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant Populations. (2020) (5)
- Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm (2016) (5)
- Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival (2019) (5)
- Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results. (2016) (5)
- The diagnostic problem of endometrial stromal sarcoma (2002) (5)
- A technical guideline: collection of adequate PAP smears of the uterine cervix (2001) (5)
- Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial (2020) (5)
- Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. (2022) (5)
- Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting (2023) (5)
- Everolimus plus exemestane in patients with advanced invasive lobular carcinoma: Efficacy and safety results from BOLERO-2. (2014) (5)
- FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer (2021) (5)
- Aromatase Inhibitors in Premenopausal Women: The Need for Proper Contraceptive Counseling (2006) (5)
- Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2. (2013) (4)
- OC001: Prospective assessment of simple rules to distinguish between malignant and benign adnexal masses prior to surgery (2008) (4)
- Pan-cancer detection and typing by mining patterns in large genome-wide cell-free DNA sequencing datasets (2022) (4)
- Bilateral Mammary Tuberculosis Associated with a Borderline Ovarian Tumor (2008) (4)
- Endometrial cancer: predictors of response and preferred endocrine therapy. (2006) (4)
- Wilms’ tumour gene 1 (WT1) positivity in endothelial cells surrounding epithelial uterine tumours (2009) (4)
- Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial (2020) (4)
- Genetic variation at CYP 3 A is associated with age at menarche and breast cancer risk : a case-control study (2014) (4)
- Prospective study evaluating the effect of impaired tamoxifen metabolisation on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting. (2016) (4)
- Juvenile Papillomatosis: A Case Report. (2019) (4)
- Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses (2022) (4)
- Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from trial BIG 1-98 comparing adjuvant endocrine therapy with tamoxifen versus letrozole (2008) (4)
- False-negative tests in breast cancer management. (2011) (4)
- Hormonal interventions and cancer risk (1995) (4)
- Laparoscopic para- aortic lymphadenectomy and positron emission tomography scan as staging procedures in patients with cervical carcinoma stage IB2–IIIB (2007) (4)
- Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Women With Early Breast Cancer: Results From the BIG 1-98 Collaborative Groups (2007) (4)
- Are gene signatures better than traditional clinical factors? (2008) (4)
- P5-16-02: The Impact of Educational Materials on Compliance and Persistence with Adjuvant Aromatase Inhibitors: 2 Year Follow-Up and Final Results from the CARIATIDE Study. (2011) (4)
- 331P Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML) -3 and -7 (2020) (4)
- The estrogen receptor has a prognostic value in progesterone receptor-positive breast cancer (2006) (4)
- Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer (2022) (4)
- Neoadjuvant capecitabine (X), docetaxel (T)±trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): preliminary safety and efficacy data from a multicentre phase II study (2006) (4)
- BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor for the Treatment of Patients with HER2-Negative Metastatic Breast Cancer after Failure of No More Than Two Prior Chemotherapies. (2009) (4)
- Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) (2012) (4)
- Fertility preservation in (breast) cancer patients: is it safe? (2006) (4)
- Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation (2021) (4)
- The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value? (2017) (4)
- Diurnal variation of urinary "hCG beta subunit core fragment" production evaluated in patients with gynecological neoplasms. (1994) (4)
- Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival. (2018) (4)
- Sequential Intra-arterial Infusion of 90Y-resin Microspheres and Mitomycin C in Chemo Refractory Liver Metastatic Breast Cancer Patients: a Single Centre Pilot Study (2020) (4)
- THE POSITIVE ASSOCIATION BETWEEN BREAST TUMOR SIZE AND LYMPH NODE INVOLVEMENT IN LOBULAR BREAST CANCERS IS PROGESTERONE RECEPTOR DEPENDENT (2010) (4)
- Different outcome variables yield different results! (2013) (3)
- Correlation of Trop-2 expression with clinicopathological characteristics, sTILs, AR expression and outcome in primary TNBC. (2021) (3)
- Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2. (2022) (3)
- Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials (2019) (3)
- Prophylactic salpingo-oophorectomy in 51 women with familial breast–ovarian cancer: importance of fallopian tube dysplasia (2005) (3)
- Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial. (2018) (3)
- Erratum: The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formation [EMBO Mol Med, 5, (2013) 1523-1536, DOI: 10.1002/emmm.201302847] (2014) (3)
- The prognostic and predictive value of the progesterone receptor in women with an oestrogen receptor positive breast cancer (2004) (3)
- Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates (2021) (3)
- Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers (2016) (3)
- Tamoxifen or Aromatase Inhibitors in Breast Cancer: Efficacy and Safety (2007) (3)
- Aromatase Inhibitors and Postmenopausal Breast Cancer Patients with Tamoxifen-Induced Endometrial Pathology (2006) (3)
- Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. (2021) (3)
- Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. (2021) (3)
- 264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) (2021) (3)
- Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view. (2006) (3)
- Biology and prognosis by age of primary operable breast cancer. (2009) (3)
- Scalp cooling in breast cancer patients treated with docetaxel–cyclophosphamide: patient- and nurse-reported results (2021) (3)
- The position of neoadjuvant chemotherapy within the treatment of ovarian cancer. (2006) (3)
- Improving outcome in the first-line management of advanced ovarian cancer (2007) (3)
- The influence of body composition and hormone replacement therapy (HRT) on progesterone receptor (PR) expression in postmenopausal women with an oestrogen receptor (ER)-positive breast cancer (2006) (3)
- Abstract P3-07-46: CYPTAM-BRUT 3: Endometrial thickness cannot be used as a marker for tamoxifen metabolization in postmenopausal breast cancer patients (2016) (3)
- Effect of cancer prevalence on the use of risk‐assessment cut‐off levels and the performance of mathematical models to distinguish malignant from benign adnexal masses (2011) (3)
- Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancer. (2015) (3)
- Abstract PD2-2: Body mass index (BMI) and treatment outcome of breast cancer patients receiving neoadjuvant therapy (NACT) (2013) (3)
- Risk-reducing mastectomy in BRCA carriers: survival is not the issue (2019) (3)
- Uterine ultrasound and endometrial biopsy in tamoxifen users (2020) (3)
- Cognitions and physical impairments in relation to upper limb function in women with pain and myofascial dysfunctions in the late stage after breast cancer surgery: an exploratory cross-sectional study (2021) (3)
- 233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) (3)
- Malignancies in Pregnancy 2 Breast cancer in pregnancy (2012) (3)
- Which questionnaire to measure psychosocial effects of having an abnormal PAP smear? (1996) (3)
- PORT SITE METASTASES ARE FREQUENT AFTER OPEN LAPAROSCOPY IN PATIENTS WITH ADVANCED OVARIAN CARCINOMA, BUT DO NOT INFLUENCE THE SURVIVAL: AN ANALYSIS OF 173 CASES (2003) (3)
- Activity of fulvestrant in HER 2-overexpressing advanced breast cancer (2010) (3)
- Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study. (2013) (3)
- Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC). (2011) (3)
- Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer (2021) (3)
- Docetaxel (T) + capecitabine (X) with or without trastuzumab (H) neoadjuvant therapy for locally advanced breast cancer (BC): Phase II study (2007) (3)
- The prognostic role of the androgen receptor in patients with triple-negative early breast cancers and primary surgery. (2019) (2)
- Postoperative evolution of thickness and echogenicity of cutis and subcutis of patients with and without breast cancer-related lymphedema. (2014) (2)
- A Phase II Study (FINDER 2) Comparing Three Dosing Regimens of Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer. (2009) (2)
- Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers (2021) (2)
- Tamoidfen: the need for a monitoring protocol (1996) (2)
- Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer (2022) (2)
- P106 A lack of evidence for the genotoxicity of tamoxifen and toremifene in the human endometrium (1998) (2)
- Abstract P5-19-02: Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04) (2015) (2)
- Oestrogen and female cancers. the past 100 years. (2000) (2)
- Prospective study of uterine sonographic changes after 3 months endocrine treatment in postmenopausal breast cancer patients: tamoxifen is estrogenic while aromatase inhibitors induce atrophy and can reverse the effect of tamoxifen (2003) (2)
- Reply to H.A. Azim Jr et al (2010) (2)
- Abstract P2-12-06: Ultra-low dose vaginal estriol and Lactobacillus acidophilus (Gynoflor®) in early breast cancer survivors on aromatase inhibitors: Pharmacokinetic, efficacy and safety results from a phase I study. (2012) (2)
- P3-08-02: Evaluating the Impact of Educational Material on Anastrozole Treatment Adherence – The Final Results of the ARTEMIS Study. (2011) (2)
- Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses. (2018) (2)
- Extended adjuvant letrozole following five years of tamoxifen is cost-effective from a Belgian health care payer's perspective (2006) (2)
- Abstract 766: Clinical outcomes of patients withPIK3CAmutations in circulating tumor DNA: Update from the MONARCH 2 study of abemaciclib plus fulvestrant (2020) (2)
- Levonorgestrel-releasing intra-uterine systems (LNG-IUS) and breast cancer. (2009) (2)
- Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease (2022) (2)
- Is the sentinel lymph node biopsy more sensitive for the identification of positive lymph nodes in breast cancer than the axillary lymph node dissection? (2013) (2)
- Low 25-hydroxyvitamin d3 serum levels are associated with larger breast tumor size (2011) (2)
- P289 Prospective study to assess fluid accumulation and tendosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome – 2 year follow-up data (2011) (2)
- Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial (2023) (2)
- The progesterone receptor has a prognostic value in oestrogen receptor negative breast cancers (2004) (2)
- Endocrine treatment and prevention of breast and gynaecological cancers (2002) (2)
- Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population (2020) (2)
- The decrease in grip strength in aromatase inhibitor-induced arthralgia is associated with extremes in body mass index and increased tenosynovial abnormalities. (2009) (2)
- P2-17-09: A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors or Tamoxifen. (2011) (2)
- The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses. (1993) (2)
- Prospective study on the effect of endocrine treatments on menopausal symptoms in breast cancer patients (2003) (2)
- Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations (2018) (2)
- Tamoxifen and the uterus : potential uterine risks of anti-oestrogens (1998) (2)
- Impact of a compression garment, on top of the usual care, in patients with breast cancer with early disturbance of the lymphatic transport: protocol of a randomised controlled trial (2020) (2)
- Abstract P6-07-29: Independent prognostic value of age depends on breast cancer subtype (2012) (2)
- Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial (2022) (2)
- VI.6 Detection of DNA adducts in the human endometrium: a lack of evidence (1998) (2)
- Neoadjuvant capecitabine (X) plus clocetaxel (T) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data (2005) (2)
- Magnetic Seed Localization for Nonpalpable Breast Lesions: First experiences (2018) (2)
- ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer. (2011) (2)
- Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2 (2021) (2)
- Reply to C.L. Braal et al, H. Brauch et al, and M.P. Goetz et al. (2019) (2)
- Screening for neural tube defect with maternal serum a-fetoprotein and ultrasound without the use of amniocentesis (1991) (2)
- Corrigendum The (2014) (2)
- Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer (2022) (2)
- Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC). (2022) (2)
- Importance of synovial fluid retention and tickening in patients with severe musculoskeletal pain treated with letrozole or exemstance: a case series describing the impact of symptoms, clinical findings and magnetic resonance imaging (2006) (2)
- Preoperative FDG-PET/CT can change the tumour stage in locally advanced breast cancer (2005) (2)
- Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study (2017) (2)
- A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen. (2018) (2)
- New SERMs in development. (2002) (2)
- Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole (2010) (2)
- III.1 Tamoxifen and the uterus—the hysteroscopic approach (1998) (2)
- Anastrozole and fulvestrant in metastatic breast cancer. (2012) (2)
- P5-05-01: Vitamin D Status in Newly Diagnosed Breast Cancer Patients Inversely Correlates with Tumor Size and Moderately Correlates with Outcome. (2011) (2)
- Hormone receptor expression in Flemish patients with in situ and invasive primary breast cancer (2002) (2)
- Two truncating variants in FANCC and breast cancer risk (2019) (2)
- Molecular characterization of early-stage her2-overexpressing breast cancer (her2+ bc) treated with adjuvant trastuzumab: identification of prognostic groups (2012) (2)
- 401 Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors or Tamoxifen (2012) (2)
- Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer (2020) (2)
- Chromosomal instability in cell-free DNA as a highly specific biomarker for ovarian cancer detection (2016) (2)
- Endometrial changes during tamoxifen treatment (1998) (2)
- P3-14-22: Response to Neoadjuvant Chemotherapy in Elderly Patients with Locally Advanced Breast Cancer. (2011) (1)
- Advances in the treatment of oestrogen receptor positive advanced breast cancer (2017) (1)
- LBA5_PR Abemaciclib in high risk early breast cancer (2020) (1)
- Endocrine therapy for metastatic endometrial cancer (2004) (1)
- Endometrial Surveillance of Tamoxifen Patients (2003) (1)
- Everolimus in combination with Exemestane in hormone receptor-positive, locally advanced or metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors (NSAIs) : BALLET study (CRAD001YIC04) (2015) (1)
- Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy (2022) (1)
- Abstract GS1-09: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes (2023) (1)
- Role of lymphadenectomy in patients with clinical FIGO stage I endometrial adenocarcinoma (2006) (1)
- 2MO Abemaciclib in high risk early breast cancer (2020) (1)
- PCN44 ADJUVANTTRASTUZUMAB TREATMENT IN EARLY STAGE BREAST CANCER: COST-EFFECTIVENESS IN THE BELGIAN HEALTH CARE SETTING (2007) (1)
- Age specific variation of oestrogen and progesterone receptor expression in 1340 primary operable breast cancers (2004) (1)
- 32P Ageing Biomarkers in an Elderly Breast Cancer Population: Correlation with Comprehensive Geriatric Assessment (CGA) (2012) (1)
- Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data (2014) (1)
- Abstract S6-03: Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS) (2016) (1)
- P2-17-01: Influence of Delayed Zoledronic Acid Initiation on Disease-Free Survival in Postmenopausal Women with Endocrine Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole: Exploratory Analyses from the ZO-FAST Trial. (2011) (1)
- Fulvestrant in the treatment of HER2-positive advanced breast cancer (ABC) (2007) (1)
- THE IMPORTANCE OF HORMONES IN THE TREATMENT OF ENDOMETRIAL STROMAL SARCOMA: AN UPDATE (2003) (1)
- Abstract P6-08-03: Germline mutational landscape in 5422 individuals at risk for hereditary breast and ovarian cancer who underwent multi-gene panel testing (2020) (1)
- 144P Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) (1)
- Immune cell dynamics induced by a single dose of pembrolizumab as revealed by single-cell RNA profiling. (2019) (1)
- 0134 CARIATIDE study: Evaluation of the impact of educational material on the compliance and persistence rates to adjuvant aromatase inhibitor (AI) medication for postmenopausal women with hormone sensitive early breast cancer (2009) (1)
- Endocrine treatment and prevention of breast and gynaecological cancers. (2004) (1)
- Elevated CA 15.3 in Newly Diagnosed Breast Cancer: A Retrospective Study. (2022) (1)
- P03 Management of ovarian cysts in premenopausal women with tamoxifen (2019) (1)
- Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy - Reply (2014) (1)
- ARE BREAST CANCERS IN PATIENTS ON HORMONE REPLACEMENT THERAPY DIFFERENT FROM THE CLASSICAL BREAST CANCER? (2003) (1)
- Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. (2022) (1)
- Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26-28, 2006. (2006) (1)
- Effect of tamoxifen on bone. (1993) (1)
- Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer (2023) (1)
- PROPHYLACTIC SALPINGO-OOPHORECTOMY IN 46 WOMEN WITH A FAMILY HISTORY OF BREAST AND/OR OVARIAN CARCINOMA (2003) (1)
- Abstract P1-01-05: Influence of age and tumor size on lymph node positivity in breast cancer: A retrospective population study on the US SEER database (2022) (1)
- Imaging the endometrium in postmenopausal bleeding (2018) (1)
- Adverse events with everolimus in BOLERO-2. (2014) (1)
- Assessment of hot flashes and clinical correlates in breast cancer patients receiving tamoxifen or third-generation aromatase inhibitors (2005) (1)
- 817P Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial (2020) (1)
- 2022-RA-884-ESGO Whole-body diffusion-weighted MRI (WB-DWI/MRI) for the prediction of resectable disease at the time of secondary cytoreductive surgery for relapsed epithelial ovarian cancer (2022) (1)
- 175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study (2022) (1)
- Abstract P6-09-11: Independent prognostic value of age depends on breast cancer subtype (2016) (1)
- Tamoxifen and potential adverse effects (1993) (1)
- S12 Five year results of a randomised placebo controlled trial of lasofoxifene (PEARL) on the incidence of ER positive breast cancer in postmenopausal women with osteoporosis (2009) (1)
- Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI). (2014) (1)
- 2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer (2022) (1)
- Abstract PD4-1: Timing, severity and risk factors for arthralgia in the IBIS-II trial: A retrospective and exploratory analysis (2015) (1)
- Abstract P6-07-19: Prognostic relevance of PR and detection mode in Luminal Her-2 negative breast cancer (2012) (1)
- Euralox 1: uterine safety of kilogest versus evista : preliminary results (2002) (1)
- MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer (2021) (1)
- 55P Prognostic Role of Palpability in Screen Detected Breast Cancer (BC) (2012) (1)
- Laparoscopic hysterectomy for early endometrial cancer. (2010) (1)
- Why should results from metastatic trials no longer matter for early-stage disease? (2013) (1)
- A controlled clinical study on tamoxifen and the endometrium. (1994) (1)
- Detection and diagnosis (2012) (1)
- Abstract P2-09-03: Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC (2017) (1)
- Abstract S5-3: Is Manual Lymph Drainage Applied after Axillary Lymph Node Dissection for Breast Cancer Effective To Prevent Arm Lymphoedema? A Randomised Controlled Trial (2010) (1)
- 0033 Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women by baseline estradiol levels (2009) (1)
- Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (1)
- Abstract P5-09-05: Hereditary breast cancer beyond BRCA: Clinical and histopathological characteristics in patients with germline CHEK2, ATM, PALB2 and TP53-mutations (2019) (1)
- Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period (2021) (1)
- Abstract P6-09-07: Impact of comprehensive geriatric assessment on treatment decision and follow-up in older breast cancer patients (2012) (1)
- Manual lymph drainage to prevent arm lymphoedema after axillary dissection for breast cancer (2012) (1)
- MONARCH 2: subgroup analysis of patients receiving abemaciclib+fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer (ABC) (2020) (1)
- Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies (2022) (1)
- Abstract P1-13-08: Arthralgia and changes in serum levels of IGF-I, its binding protein and estrogen in breast cancer patients on endocrine agents (2013) (1)
- Abstract P5-06-28: Optimization and validation ofPIK3CAmutation detection with droplet digital PCR in liquid biopsies of patients with metastatic breast cancer (2020) (1)
- Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (2021) (1)
- Radical vulvectomy using the argon enhanced electro‐surgical pencil (1993) (1)
- Adverse events with everolimus in BOLERO-2. (2014) (1)
- 44P Prognostic Value of Detection Method by Breast Cancer (BC) by Phenotype (2012) (1)
- 220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD (2022) (1)
- Validation of a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer (2019) (1)
- Abstract PD8-07: Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer (2021) (1)
- Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort (2021) (1)
- Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the “SOLE” trial. (2018) (1)
- Abstract P6-09-12: A consecutive series of early breast cancers with a low estrogen receptor expression (2017) (1)
- P343 CARIATIDE trial: the impact of educational materials (EM) on patients' compliance with adjuvant aromatase inhibitor (AI) therapy and quality of life (QoL) (2011) (1)
- Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial (2020) (1)
- 336 Retrospective CYPTAM-BRUT 1 Study Shows Association Between the Genetic Variants Rs1800716 and Rs727479 in Tamoxifen Metabolisation and Tamoxifen-induced Increase in Double Endometrial Thickness (2012) (0)
- Abstract P3-07-14: Multigene signatures based risk estimates in early ER+/HER2- breast cancer: The predictive value of inexpensive statistical models and changes in adjuvant chemotherapy use (2019) (0)
- Expression of the BRCA1 interacting protein Brip1 is controlled by E2F and correlates with breast cancer malignancy (2008) (0)
- INDICATIONS FOR AND FINDINGS AT DUCT EXCISION FOR SINGLE DUCT NIPPLE DISCHARGE (2003) (0)
- A MULTICENTRE RANDOMISED TRIAL TO COMPARE UTERINE SAFETY OF RALOXIFENE WITH A CONTINUOUS COMBINED HORMONE REPLACEMENT THERAPY CONTAINING OESTRADIOL AND NORTHISTERONE ACETATE (2003) (0)
- P105 The MAGIC survey in HR+, HER2− breast cancer (BC): when might multigene assays be of value? (2015) (0)
- Abstract P3-08-01: MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors (2020) (0)
- 0090 Axillary staging of breast cancer with the sentinel lymph node (SLN) procedure in over a thousand patients with early breast cancer (2009) (0)
- Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors (2014) (0)
- Abstract HER2-16: HER2-16 Inter-lesion heterogeneity of HER2-status in metastatic breast cancer: possible implications for treatment with anti-HER2 antibody-drug conjugates (2023) (0)
- Everolimus (EVE) plus exemestane (EXE) in elderly patients (pts) with hormone receptor-positive (HR+), human epidermal growth receptor-2 negative (HER2-) advanced breast cancer (ABC) progressing on prior nonsteroidal aromatase inhibitors (NSAIs) : Insights on safety form BALLET (CRAD001YIC04) (2016) (0)
- Changes in transforming growth factor Beta levels in human endometrium associated with tamoxifen treatment (2001) (0)
- Clinical outcomes of patients with PIK3CA mutations in circulating tumor DNA: update from the MONARCH 2 study of abemaciclib plus fulvestrant (2021) (0)
- Clinicopathologic features of 59 pleomorphic lobular carcinomas of the breast (2003) (0)
- Abstract OT2-11-04: Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (2022) (0)
- Reply to A.C. Voogd et al (2009) (0)
- Abstract P6-08-05: Prognostic value of the progesterone receptor by proliferation rate in patients with luminal HER2 negative breast cancer (2015) (0)
- The oestrogen receptor interacts with the correlation between HER-2 over-expression and age at diagnosis, tumour grade and lymph node involvement in operable breast cancers: a single centre experience (2008) (0)
- 147 Factors predicting disease free survival following neoadjuvant chemotherapy for breast cancer (2010) (0)
- The value of PET-CT in patients with a suspicious pelvic mass (2011) (0)
- Serum methylmalonic acid concentrations at breast cancer diagnosis are not associated with distant metastases (2022) (0)
- Abstract P5-18-19: The 2006 Adjuvant Trastuzumab Convention in Belgium: 5 years later (2012) (0)
- Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival (2023) (0)
- Magnetic Seed Localisation for Non-Palpable Breast Lesions: A Comparison with Hooked-Wire (2021) (0)
- The footprint of the ageing stroma in older patients with breast cancer (2017) (0)
- Abstract P2-11-20: Challenging the current 1-10% cut-off for defining Estrogen Receptor Low Positive grade 2-3 Estrogen Receptor positive, Human Epidermal growth factor Receptor 2 negative early breast cancer (2023) (0)
- Effects of tamoxifen on uterus. (1994) (0)
- Abstract PD13-06: PD13-06 Long-Term and Very-Long-Term Disease Control in Patients From BYLieve Study Cohort A With PIK3CA-Mutant, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced Breast Cancer (2023) (0)
- Association between the progesterone receptor and HER-2/neu in oestrogen-receptor positive breast cancer (2004) (0)
- Abstract P1-15-04: Breast cancer recurrence and predictors for recurrence despite pathologic complete response following neoadjuvant chemotherapy (2019) (0)
- The impact of baseline and genetic parameters on progression free survival and overall survival in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy with fluorouracil, epirubicin, cyclophosphamide (FEC) and docetaxel (D) (2013) (0)
- Abstract P4-06-14: Single-cell RNA sequencing to delineate changes in tumor microenvironment induced by immunotherapy (2019) (0)
- Stratifying primary operable breast cancers by steroid and HER-2 expression status predicts short term disease free survival (2007) (0)
- Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials (2023) (0)
- Diurnal VarIatIon of Urinary "hCG $ Subunit Core Fragment" Production Evaluated in Patients wfth (1994) (0)
- Abstract P2-16-19: Fulvestrant with or without selumetinib (Sel, AZD6244), a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor (AI): A multicenter randomized placebo-controlled double-blind phase II trial, SAKK21/08 (2013) (0)
- EFFECTS OF TAMOXIFEN ON UTERUS. AUTHORS' REPLY (1994) (0)
- 72TiP ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast (2021) (0)
- Is weight of breast associated with hormone receptor expression in postmenopauzal breast cancer (2002) (0)
- Abstract PS7-52: The upgrade risk to (pre-)invasive breast cancer for B3 lesions diagnosed on core needle or vacuum assisted biopsy. A Belgian retrospective study (2021) (0)
- Tamoxifen and its role in endometrial cancer (2000) (0)
- Abstract PD3-09: Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer (2019) (0)
- Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2020) (0)
- Abstract P4-07-16: Correlation of Trop-2 expression with clinicopathological characteristics and outcome in triple-negative breast cancer (TNBC) (2022) (0)
- Abstract OT2-2-03: Dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine-resistant HER2–/HR+ breast cancer: a phase II study (2012) (0)
- Lymph node ratio is a better prognostic predictor for disease free survival than the number of positive lymph nodes in Node-Positive Breast Cancer (2009) (0)
- POSTMENOPAUSAL EVALUATION AND RISK-REDUCTION WITH LASOFOXIFENE (THE PEARL TRIAL): GYNAECOLOGICAL OUTCOMES AT FIVE-YEARS (2009) (0)
- Treatment efficacy and predictors of durable response to capecitabine monotherapy in advanced breast cancer: Real-world evidence from a large single-centre cohort (2020) (0)
- P115 Quality-of-life analysis in the randomized phase II CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer (2019) (0)
- 353 Safety of letrozole and tamoxifen monotherapy: updated BIG 1-98 (2010) (0)
- Microcalcificaties in de borst (2005) (0)
- Why intraperitoneal chemotherapy cannot be regarded as standard of care in patients with advanced ovarian cancer (2007) (0)
- Elderly patients with early breast cancer (BC) are less likely to receive adjuvant chemotherapy (AdjCT) irrespective of disease risk factors: The multidisciplinary application of genomics in clinical practice (MAGIC) survey (2014) (0)
- Assessment of changes in tumor biology during tumor evolution in endometrial cancer (2008) (0)
- Abstract P3-05-28: Impact of increased adiposity on extended aromatase inhibitor treatment in postmenopausal patients with estrogen receptor positive (ER+) breast cancer: a retrospective analysis of the SOLE trial (2023) (0)
- 000285 LAPAROSCOPIC PARA-AORTIC LYMPHADENECTOMY AS STAGING PROCEDURE IN PATIENTS WITH CERVICAL CARCINOMA STAGE IB2-IIIB (2005) (0)
- Abemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET). (2018) (0)
- P4-09-07: Breast Cancer Outcome by Combined Immunohistochemical ER/PR/HER2 Receptor Phenotype. (2011) (0)
- Erratum to “EUROLOX 1: Uterine safety of kilogest versus evista: preliminary results” [European Journal of Cancer, 38 Suppl 6 (2002) S83–S84] (2003) (0)
- Abstract P1-10-03: CARIATIDE: The Impact of Educational Materials and Demographic Characteristics on Compliance with Adjuvant Aromatase Inhibitor Treatment (2010) (0)
- The impact of patient-related factors on the occurrence of febrile neutropenia in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin, and cyclofosfamide (FEC) x6 or FEC x3 followed by docetaxel (D) x3. (2013) (0)
- Abstract P5-08-31: Withdrawal of exogenous hormones affects prognostic multigene signature results in early luminal breast cancer (2016) (0)
- 000469 EVALUATION OF OUTCOMES OF LAPAROTOMY FOR THE SURGICAL MANAGEMENT OF STAGE II AND III SEROUS BORDERLINE OVARIAN TUMORS (2005) (0)
- Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial (2019) (0)
- The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer (2015) (0)
- Hormone receptor status in primary postmenopausal breast cancers. Is there an association with hormone replacement therapy (2002) (0)
- P42 The age-related ER+PR+ expression differs by HER-2/neu status (2005) (0)
- Abstract PD3-1: Evaluation and clinical impact of intra-tumor heterogeneity (ITH) in primary HER2-overexpressing breast cancers (HER2+BC) treated with adjuvant trastuzumab and chemotherapy (CT) (2015) (0)
- Effect of myofascial techniques in addition to standard physical therapy for treatment of pain and upper limb problems in breast cancer survivors: Randomized controlled trial (2016) (0)
- Authors' reply (1994) (0)
- Abstract P3-08-20: Clinical next-generation sequencing analysis in ER-positive HER2-negative metastatic breast cancer patients: Mutation frequency & clinical correlations (2019) (0)
- Improving NPI for breast cancer prognosis by including PR and HER-2 expression: own data and external validation set (2009) (0)
- Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium (2020) (0)
- Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy (2018) (0)
- Quasiclassical approach to low-dimensional topological insulators and superconductors (2015) (0)
- Abstract P5-18-01: Extended continuous vs intermittent adjuvant letrozole in postmenopausal women with lymph node-positive, early breast cancer (IBCSG 37-05/BIG 1-07 SOLE): Impact on patient-reported symptoms and quality of life (2018) (0)
- Detection of sentinel lymph nodes in breast cancer : every day practice and pitfalls (2007) (0)
- ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast. (2022) (0)
- Gynaecology. Hormonal interventions and cancer risk. (1995) (0)
- Abstract P5-05-06: ctDNA detection in seven different types of body liquids in patients with metastatic breast cancer (2023) (0)
- AGGRESSIVE BIOLOGIC BEHAVIOR OF ENDOMETRIAL CARCINOSARCOMA WHEN COMPARED TO HIGH RISK EPITHELIAL ENDOMETRIAL CANCER (2004) (0)
- 000468 EFFECTIVENESS OF WEEKLY TOPOTECAN IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN CANCER (2005) (0)
- Computerized scoring tool for identification and quantification of different immune cell populations in breast tumor regions (2020) (0)
- Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. (2023) (0)
- Who needs adjuvant systemic treatment ? Predicting prognosis in node-negative breast cancer ; from bench to bedside (2009) (0)
- Abstract P1-02-04: Real world adjuvant endocrine treatment in premenopausal breast cancer patients compared with the proposed algorithm using the Regan Composite Risk Score (2023) (0)
- Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty (2017) (0)
- Abstract P6-08-06: The multidisciplinary application of genomics in clinical practice (MAGIC) survey: Identification of early stage hormone receptor-positive (HR+), HER2– breast cancer (BC) patients for whom multigene assays may be valuable (2015) (0)
- Genetic variant in the OPG gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients (2015) (0)
- Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer (2022) (0)
- Abstract P5-21-22: Palbociclib in highly pretreated metastatic ER-positive HER-2 negative breast cancer (2018) (0)
- Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial. (2018) (0)
- Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe (2015) (0)
- Boost Delineation in Breast Radiation Therapy: Isotropic Versus Anisotropic Margin Expansion (2014) (0)
- PREDICTORS OF HER-2/NEU EXPRESSION IN OPERABLE BREAST CANCER. THE IMPORTANCE OF THE PROGESTERONE RECEPTOR (2004) (0)
- Abstract P3-05-11: Breast cancer characteristics in premenopausal women by contraception method (2023) (0)
- Abstract P1-10-04: Impact of body mass index (BMI) on the predictive and prognostic value of stromal tumor-infiltrating lymphocytes (sTIL) in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NACT) (2020) (0)
- P3.13.24 The effect of raloxifene on the incidence of surgical intervention for pelvic floor relaxation (2000) (0)
- Abstract P4-02-07: Comparison of breast cancer molecular subtyping by Immunohistochemistry and by BluePrint®next generation RNA sequencing-based test at University Hospitals Leuven and Curie Institute Paris (2019) (0)
- Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry (2016) (0)
- 328 Role of the Fragile X Mental Retardation Protein in Tumor Progression and Metastasis Formation (2012) (0)
- The impact of baseline and genetic parameters on progression free survival and overall survival in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy with fluorouracil, epirubicin and cyclophosphamide (2013) (0)
- 142P Quality-adjusted survival with ribociclib plus fulvestrant (R+F) versus placebo plus fulvestrant (P+F) in postmenopausal women (PMW) HR+/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial (2020) (0)
- Impact of adjuvant chemotherapy on clinical and biological ageing in older breast cancer patients (2015) (0)
- Abstract OT2-11-02: Ameera-1 Arm 4: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with everolimus in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (2022) (0)
- Abstract P1-08-31: Comparing estimates of survival for breast cancer patients (2019) (0)
- Abstract P4-08-09: The Prognostic Importance of “Detection Mode” and “Palpability” in Primary Operable Grade 2 Breast Cancers (2010) (0)
- Abstract P4-01-42: Pooled analysis of post-progression treatments after first-line ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 studies (2023) (0)
- 66 The cariatide study: evaluation of the impact of educational material on the compliance and persistence rates to adjuvant aromatase inhibitor medication in postmenopausal breast cancer patients: baseline data (2009) (0)
- Abstract P5-04-23: Characterization of the tumor microenvironment in a large series of ER/PR negative breast cancer (2020) (0)
- Abstract P2-13-06: Effect of letrozole on bone and joints in collagen-induced arthritis in mice (2012) (0)
- P74 The proportion of women receiving adjuvant systemictherapy for breast cancer and the impact of a protocol adjuvant (2005) (0)
- P88 Analysis of 93 patients with endometrial cancer using the PROMISE classification and additional genetic analyses for MSI and POLE-EDM (2019) (0)
- P29 Age does affect the HER-2/neu status of breast cancers (2005) (0)
- Prevention of breast cancer. (1992) (0)
- The prognostic and predictive role of the androgen receptor in TNBC treated with neo-adjuvant chemotherapy. (2019) (0)
- AGGRESSIVE DEBULKING SURGERY IS FEASIBLE WITH ACCEPTABLE MORBIDITY: AN ANALYSIS OF 288 PATIENTS (2004) (0)
- REPORT OF BREAST CARCINOMA WITH CHONDROID METAPLASIA (2003) (0)
- Abstract PS10-14: Efficacy and safety of palbociclib (PAL) in patients (pts) with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with preexisting conditions: A post hoc analysis of PALOMA-2 (2021) (0)
- 000283 THE PEDICLE ARTERY SIGN BASED ON TRANSVAGINAL COLOR DOPPLER IMAGING MAY IMPROVE ENDOMETRI-AL ASSESSMENT IN BREAST CANCER PATIENTS TREATED WITH TAMOXIFEN (2005) (0)
- Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Cancer (2016) (0)
- 0579: The Role of Neoadjuvant Chemotherapy in Cervical Carcinoma Stage Ib2-Iib. Results of a Pilot Study (2006) (0)
- Intrahepatic mitomycin C infusion in breast cancer liver metastases. (2019) (0)
- Breast Cancer Guidelines Expert Panel (2013) (0)
- Abstract P1-13-09: Sensitive liquid chromatography-tandem mass spectrometry method for serum estradiol and estrone assessment without derivatisation, overcoming cross reactivity with exemestane (2013) (0)
- Abstract P1-20-24: Magnetic seed localisation as the new standard of care for nonpalpable breast lesion localisation: A comparison with hooked-wire localisation (2020) (0)
- 0192 Does the stellate ganglion block reduce severe hot flushes and sleep disturbances in breast cancer patients (2009) (0)
- Abstract P4-09-12: Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B (2023) (0)
- Abstract P6-10-06: The impact of body mass index on age at breast cancer diagnosis and breast cancer phenotype (2016) (0)
- Minimally invasive detection of tumor-specific copy number alterations in the plasma of patients with ovarian cancer (2015) (0)
- Integrative proteomic and gene expression analysis identify annexinA1 and caveolin1 as predictive biomarkers for adjuvant trastuzumab resistance. (2014) (0)
- E12. Managing toxicity of aromatase inhibitors in early breast cancer (2012) (0)
- ARandomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy forAdvanced Breast Cancer (2007) (0)
- 261PDTHE EFFECT OF PHYSICIAN'S CHARACTERISTICS ON ADJUVANT CHEMOTHERAPY (CT) DECISIONS FOR EARLY STAGE HR + , HER2- BREAST CANCER (BC) PATIENTS (PTS). (2014) (0)
- Abstract PD4-06: PD4-06 Obesity-associated changes in transcriptomic profile and immune landscape of primary breast cancer revealed by bulk and single-cell gene expression data (2023) (0)
- DIAPHRAGMATIC STRIPPING AS A TECHNIQUE TO OPTIMALLY CYTOREDUCE OVARIAN CANCER (2003) (0)
- RIBOB: A study on the efficacy and safety of ribociclib in combination with letrozole in older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior systemic therapy for advanced disease (2019) (0)
- CARIATIDE trial: the impact of educational materials (EM) on patients' compliance with adjuvant aromatase inhibitor (AI) therapy and quality of life (QoL) (2011) (0)
- P270 Outcome of HER2 positive breast cancer by PR expression since the introduction of trastuzumab (2015) (0)
- Immunohistochemical investigation of ER and PR expression in primary breast cancer and their axillary lymph node metastases (2002) (0)
- Endometrial changes in patients receiving tamoxifen therapy. (1991) (0)
- BOLERO-2: Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive ADVANCED breast cancer refractory to letrozole or anastrozole (2011) (0)
- Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (2019) (0)
- Differences between breast cancer subtypes in developing metastatic disease. (2019) (0)
- Abstract P4-03-20: Association between reproductive factors (parity and age first full term birth) and the frequency of estrogen receptor negative breast cancer according to age at diagnosis (2023) (0)
- 43P Dynamic alterations of immunosenescence-related genes in older women with breast cancer receiving chemotherapy (2022) (0)
- 0648: Clinicopathologic Analysis of Endometrial Stromal Sarcoma: Results of a Belgian Multicen-Tric Study (2006) (0)
- Adjuvant endocrine therapy in pre- and perimenopausal women with breast cancer: practice guidelines (2016) (0)
- Ribociclib + Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : MONALEESA-3 biomarker analyses (2018) (0)
- Abstract P4-18-03: IBCSG BIG 1-98 study: The long-term follow-up experience: (2015) (0)
- 295PTRADITIONAL PROGNOSTIC FACTORS USED FOR ADJUVANT CHEMOTHERAPY (CT) DECISIONS IN EARLY STAGE HR + , HER2- BREAST CANCER IN A LARGE INTERNATIONAL SURVEY (MAGIC) AMONG BREAST CANCER SPECIALISTS. (2014) (0)
- 1109 Quality of life and sexual functioning after treatment for locally advanced cervical cancer – CCRT versus NACT-S (2021) (0)
- Metastasis by semi-quantitative oestrogen receptor expression in stage I-III early diagnosed triple positive breast cancer patients. (2020) (0)
- Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma (2004) (0)
- Cross Reactivity between the Roche Elecsys® Progesterone Assay and Exemestane. (2009) (0)
- Early detection of cardiac effects of pegylated liposomal doxorubicine in elderly breast cancer patients using strain rate imaging (2007) (0)
- Abstract P6-01-47: Stromal tumor infiltrating lymphocytes and pathological complete response in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy (2023) (0)
- Abstract P4-07-08: Age-related microRNAs and their biomarker potential in chemotherapy-treated older breast cancer patients (2017) (0)
- Abstract P3-03-32: Monocentric experience with the sentinel lymph node biopsy prior to neoadjuvant chemotherapy in clinically lymph node negative early breast cancer (2019) (0)
- Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (2023) (0)
- 157. Comparing medical oncologists' and surgeons' treatment recommendations in early stage HR+, HER2– breast cancer (BC) patients (pts): A subanalysis of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey (2014) (0)
- Characterization of Breast Cancer Subtypes by Immunohistochemistry in a Large Retrospective Study (2007) (0)
- PROPHYLACTIC SALPINGO-OOPHORECTOMY IN 51 WOMEN WITH FAMILIAL OVARIAN-BREAST CANCER: IMPORTANCE OF FALLOPIAN TUBE DYSPLASIA (2004) (0)
- Is weight of the breast associated with hormone receptor expression in postmenopausal women with invasive breast cancer (2002) (0)
- 00039 PROPHYLACTIC MASTECTOMY IN HIGH-RISK FAMILIES FOR BREAST CANCER AT THE UNIVERSITY HOSPITALS OF LEUVEN - BELGIUM (2005) (0)
- uPAR gene amplification in breast cancer tissue: a rare event (2007) (0)
- Abstract P6-08-02: The body mass index interacts with the prognostic effect of the progesterone receptor in patients with a luminal HER2 negative breast cancer (2015) (0)
- EP1218 Outcome in 186 patients with cervical cancer stage IB1 treated with radical hysterectomy without adjuvant radiochemotherapy, unless presenting with metastatic lymph nodes (2019) (0)
- NEOADJUVANT USE OF FEC-100 IN LOCALLY ADVANCED NON-METASTATIC BREAST CANCER (LABC). A RETROSPECTIVE REVIEW OF 26 CASES (2004) (0)
- Abstract P4-01-29: Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2- metastatic breast cancer (2023) (0)
- Abstract P3-12-12: Serum estrogen-levels in women 48-56yrs with hormone receptor-positive breast cancer. Cross-Sectional study using an ultra-sensitive LC-MS/MS-method (2018) (0)
- 2022-RA-1473-ESGO Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in recurrent ovarian cancer – results of the Leuven HRD test (2022) (0)
- Abstract P1-10-07: The presence of ductal carcinoma in situ in core needle biopsy and microcalcifications on mammography in TNBC is associated with a lower pCR and worse long term outcome (2020) (0)
- Are lobular carcinomas more often steroid receptor positive (2004) (0)
- The Genomic Grade Index (GGI) – a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial (2008) (0)
- Abstract P4-08-25: Decentralized beta testing of MammaPrint and BluePrint NGS kit at University Hospitals Leuven and Curie Institute Paris (2019) (0)
- Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers. (2013) (0)
- The Leuven dose-dense Paclitaxel/Carboplatin regimen as treatment for primarily advanced or recurrent endometrial cancer (2008) (0)
- Human epidermal growth factor receptor 2 mutations and androgen receptor: new therapeutic targets in breast cancer? (2015) (0)
- Breast cancer chemoprevention in the high-risk patient (2008) (0)
- Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial (2021) (0)
- 0486: Evaluation of Sentinel Lymph Node (Sln) Procedure in Cervical Cancer (2006) (0)
- Pooled Analysis of Safety and Dose Reductions in the MONALEESA-2, -3, and -7 Phase III Trials on Ribociclib Plus Endocrine Therapy to Treat Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (2020) (0)
- 0105 Is there a promotion of metastasis by autologeous breast reconstruction in patients with invasive breast cancer (2009) (0)
- Recovery of ovarian function after chemotherapy-induced amenorrhea in a patient receiving an aromatase inhibitor leads to tumor stimulation (2008) (0)
- Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) in Europe. (2013) (0)
- Fulvestrant in heavily pretreated patients with advanced breast cancer: A Belgium cooperative study. (2006) (0)
- Abstract P4-03-01: The footprint of the aging stroma in older breast cancer patients (2017) (0)
- Abstract P6-07-05: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial (2012) (0)
- Tamoxifen in premalignant and pre-invasive breast cancer. (1993) (0)
- P3-07-40: Impact of the Sentinel Lymph Node Procedure on the Detection of Positive Lymph Nodes in Breast Cancer. (2011) (0)
- 128P Characteristics, patterns of care and outcomes of young women with breast cancer (BC) according to age, year of diagnosis and germline BRCA status (gBRCA) (2021) (0)
- Inter-rater reliability in the assessment of stromal characteristics in ductal carcinoma in situ of the breast: how consistent are we? (2017) (0)
- ENDOMETRIAL CHANGES DURING TAMOXIFEN TREATMENT. AUTHORS' REPLY (1998) (0)
- Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer (2022) (0)
- The 2006 Adjuvant Trastuzumab Convention in Belgium: 5 years later (2012) (0)
- Abstract P3-05-35: The impact of parity and age of first full term pregnancy on the prevalence of invasive lobular carcinoma in patients with breast cancer (2023) (0)
- PD-0321: Risk factors for local-regional recurrences after mastectomy and adjuvant radiotherapy for breast cancer (2013) (0)
- Abstract OT2-1-05: Prospective multicenter study evaluating the effect of impaired tamoxifen metabolization on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting - The CYPTAM-BRUT 2 trial (2012) (0)
- Abstract P3-08-31: Clinical and pathological features of invasive micropapillary carcinoma of the breast and correlation with prognosis (2020) (0)
- Is weight of breast associated with hormone receptor expression in postmenopausal invasive breast cancer (2002) (0)
- RAPID COMMUNICATION The Effect of Raloxifene on the Incidence of Ovarian Cancer in Postmenopausal Women 1 (2002) (0)
- Clinicopathological features of inflammatory versus noninflammatory locally advanced non-metastatic breast cancer (2008) (0)
- Relationship between tumor size and lymp node status by 2011St. Gallen Breast Cancer Phenotype (2013) (0)
- Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition? (2023) (0)
- BELGIAN SPECIALISTS' VIEW ON THE ADJUVANT TREATMENT OF HORMONE-DEPENDENT NON-METASTATIC BREAST CANCER? (2003) (0)
- Abstract P1-12-02: Predictive variables of additional contacts with breast cancer counselors after sentinel lymph node negative breast conserving surgery in postmenopausal women (2013) (0)
- 435 Genetic Variability in the Methylenetetrahydrofolate Reductase (NAD(P)H) Gene (MTHFR) is Associated with Severe Non Hematological Toxicity of Adjuvant FEC in Breast Cancer (2012) (0)
- The impact of body mass index on age at breast cancer diagnosis and breast cancer phenotype (2015) (0)
- Abstract P6-10-13: Associated ductal carcinoma in situ in primary operated TNBC is associated with a longer time to distant event (2020) (0)
- Abstract P1-03-14: Assessment of stromal characteristics in ductal carcinoma in situ of the breast: An inter-observer variability study (2017) (0)
- Patterns of canonical and non-canonical TGFβ signaling in inflammatory breast cancer cells on cancer cell motility. (2016) (0)
- Abstract P5-14-06: The effect of adjuvant chemotherapy in a large consecutive series of ER-pos HER-2 negative early breast cancers (2017) (0)
- Abstract 507: Trop-2 expression in triple-negative breast cancer according to histological subtype: correlations with tumor infiltrating lymphocytes (TILs) and survival (2022) (0)
- Abstract P4-06-16: Analysis of tumor infiltrating lymphocytes in three age categories of luminal B-like breast cancer patients and its correlation with lymph node involvement and systemic immunosenescence/frailty markers (2019) (0)
- 182P Radium-223 (223Ra) in combination with exemestane and everolimus (EXE-EVE) in patients (pts) with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) with bone metastases: A phase II study (2022) (0)
- Treatment decision in early stage ER+ HER2− breast cancer without the 70-gene signature test: a retrospective analysis (2017) (0)
- Efficacy of CDK 4/6 inhibition after fulvestrant in metastatic breast cancer (2018) (0)
- Any questions: How long is it safe to take tamoxifen? (1997) (0)
- Managing the side effects of oral aromatase inhibitors (2012) (0)
- GEMCITABINE IN RECURRENT PLATINUM AND PACLITAXEL RESISTANT OVARIAN CARCINOMA: AN ANALYSIS OF 50 CASES (2003) (0)
- Is There Benefit to Using a Preoperative Computed Tomography to Reduce the Interobserver Variability of the Boost CTV Delineation for Breast Radiation Therapy (2013) (0)
- 000334 LAPAROSCOPIC ASSISTED VAGINAL HYSTERECTOMY OR ABDOMINAL HYSTERECTOMY IN CLINICAL FIGO STAGE I OR IIA ENDOMETRIAL CANCER (2005) (0)
- Reply to 'Age-related variations in the use of axillary staging may explain the increased risk of axillary lymph node involvement in older women with breast cancer' by Adri Voogd et al (2009) (0)
- The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars (2019) (0)
- Association of rs12662670 with breast cancer in Asian ER (2012) (0)
- Abstract P2-14-23: Outcome of patients with triple-negative breast cancer who did not receive adjuvant chemotherapy (2020) (0)
- ADJUVANT THERAPY FOR HORMONE-DEPENDENT BREAST CANCER (2003) (0)
- Bowel obstruction in advanced tubo-ovarian cancer: A retrospective cohort study (2023) (0)
- Gynaecological Assessment of Postmenopausal Women with an Asymptomatic Thickened Endometrium While on Tamoxifen: Results from a Double Blind Randomized Controlled Trial Comparing Continuation of Tamoxifen and Anastrozole. (2009) (0)
- Cancer surveillance in adults with germline TP53 pathogenic variants: A single-center observational study. (2021) (0)
- Factors predicting the axillary lymph node status in women with an ER-positive breast cancer are age-dependent (2005) (0)
- RIBOCICLIB (RIB) + LETROZOLE (LET) IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL RECEPTOR-2–NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC) BY DOSE INTENSITY: PRELIMINARY SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL (2019) (0)
- The effect of myofascial and physical therapy on trunk, shoulder, and elbow movement patterns in women with pain and myofascial dysfunctions after breast cancer surgery: secondary analyses of a randomized controlled trial. (2023) (0)
- Three-year follow-up of an adjuvant Phase II study looking at dose densification and altering sequence of the FEC-Doc regimen in patients with early breast cancer (2010) (0)
- Correction to: Behavior of metastatic breast cancer according to subtype (2021) (0)
- Genomic instability in high-grade serous ovarian cancer - development of a cell-free DNA based biomarker (2015) (0)
- P1-08-20: Parity Interferes with the Effect of Age at Diagnosis on the Frequency Breast Cancers Are Triple-Negative. (2011) (0)
- The impact of genetic variability on severe toxicity of (neo-) adjuvant chemotherapy in breast cancer patients receiving 5-fluorouracil, epirubicin, and cyclofosfamide (FEC). (2012) (0)
- III.6 Tamoxifen-induced changes of the uterus: MRI features (1998) (0)
- P32 Axillary lymph node involvement in breast cancer decreases with age but increases again after age 70 mainly in small tumors (2007) (0)
- Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer (2015) (0)
- P2-06-02: FOXO3a Genotype Predicts Age of Breast Cancer Onset and Correlates with Lymph Node Involvement. (2011) (0)
- Influence of body mass index on breast cancer features (2014) (0)
- EFFECT OF LETROZOLE ON UTERUS WEIGHT AND BONE IN DBA/1 MICE (2013) (0)
- Abstract P3-08-26: Clinico-pathological characteristics of metaplastic breast cancer as compared to normal TNBC: A single center analysis (2020) (0)
- The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort Study. (2023) (0)
- Reply to D. Crivellari et al. (2014) (0)
- Solving current dilemmas in the adjuvant endocrine treatment of pre- and perimenopausal women with an estrogen receptor positive breast cancer (2021) (0)
- Abstract P2-10-12: How well predict the 2011 St Gallen early breast cancer surrogate phenotypes metastatic survival? (2012) (0)
- Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (2019) (0)
- Abstract PD6-03: PD6-03 Serum methylmalonic acid concentrations at breast cancer diagnosis strongly correlate with frailty: a retrospective cross-sectional study (2023) (0)
- Data for: Loss of 1p36.33 frequent in low grade serous ovarian cancer (2019) (0)
- Tumour immune infiltrate characterization in luminal breast cancer in three distinct age categories and its correlation with frailty (2019) (0)
- External validation of a piecewise effect model of axillary lymph node involvement in elderly breast cancer patients (2008) (0)
- Abstract P2-11-11: Impact of baseline body mass index (BMI) and weight changes after diagnosis in young women with early breast cancer (BC): A multicenter retrospective study (2022) (0)
- The changing role of the axillary dissection in the treatment of breast cancer (2012) (0)
- 29 Factors predicting a pathological complete response following neoadjuvant chemotherapy for breast cancer (2010) (0)
- The fragile X mental retardation protein (FMRP) expression is associated with better distant metastasis free survival in a cohort of luminal-B like early breast cancers with long follow-up (2018) (0)
- Abstract OT2-11-03: AMEERA-1 : Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-)PIK3CA-mutated advanced breast cancer (2022) (0)
- Abstract P4-09-01: Impact of adjuvant chemotherapy on clinical and biological ageing in older breast cancer patients (2015) (0)
- elevated aerum markers in non invasive breast cancer five cases and review of literature introduction (2017) (0)
- RADICAL HYSTERECTOMY USING CLAMPS OR SHARP DISSECTION FOR PARAMETRIAL RESECTION: AN ANALYSIS OF 95 CASES (2003) (0)
- Effect of myofascial techniques for treatment of pain and upper limb problems in breast cancer survivors: short term beneficial effects (2016) (0)
- Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer (2022) (0)
- Extending the Developmental Origins of Health and Disease theory: does paternal diet contribute to breast cancer risk in daughters? (2016) (0)
- HER-2/neu is associated with axillary nodal invasion in breast cancers expressing both hormone receptors (2005) (0)
- The pedicle artery sign based on transvaginal color Doppler imaging may improve endometrial assessment in breast cancer patients receiving tamoxifen (2005) (0)
- Abstract P5-06-08: Predicting distant recurrence of ER+ HER2- breast cancer after 5 years of endocrine therapy: The CTS5-tool validation in real life (2020) (0)
- PROGNOSTIC FACTORS FOR IPSILATERAL BREAST CANCER (BC) RECURRENCE (2004) (0)
- 0283: Phase II Study of the “Leuven” Weekly Paclitaxel/Carboplatin Regimen in 31 Patients with Recurrent Ovarian Cancer (2006) (0)
- Abstract P6-10-06: A preoperative window-of-opportunity study of imlunestrant in estrogen receptor-positive, HER2-negative early breast cancer: Results from the EMBER-2 study (2023) (0)
- EP877 Intestinal (sub)obstruction in ovarian cancer patients: management, complications and survival (2019) (0)
- P5-14-21: Predicting the Status of the Axillary Lymph Nodes in 1300 Consecutive Patients with Early Breast Cancer Treated in a Single Institution. (2011) (0)
- BREAST CANCER VARIABLES BY OESTROGEN/PROGESTERONE RECEPTOR EXPRESSION (2004) (0)
- DETAILED ANALYSIS OF TUMOR INFILTRATING LYMPHOCYTES IN THREE AGE CATEGORIES OF BREAST CANCER PATIENTS: CORRELATION WITH SYSTEMIC IMMUNOSENESCENCE/FRAILTY MARKERS (2019) (0)
- A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer (2018) (0)
- 333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer (2021) (0)
- Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data (2023) (0)
- 'Fracture incidence after 3 years of aromatase inhibitor therapy'. (2014) (0)
- Sentinel lymph node involvement in ductal carcinoma in-situ of the breast: two different causes. (2012) (0)
- Women under age 50 with an ER-positive breast cancer are more likely to have positive lymph nodes if PR is not expressed (2004) (0)
- Prospective assessment of clinical rheumatologic features and magnetic resonance imaging (MRI) changes in the aromatase inhibitor (Al)-associated arthralgia syndrome (2008) (0)
- 43P Prognostic Value of Detection Mode in Over 1000 Consecutively Treated Grade 2 Breast Cancers (BC) (2012) (0)
- DOWN-REGULATION OF HYPOXIA INDUCIBLE FACTOR-1_(HIF-1_) EXPRESSION, THROUGH MTOR PATHWAY, BY LETROZOLE IN ER plus VE BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS (2009) (0)
- Abstract P6-09-12: Breast cancer characteristics and the levonorgestrel intrauterine device. A monocentric retrospective study (2016) (0)
- Abstract P1-19-22: Pearl or the use of FDG positron emission tomography imaging as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer (2020) (0)
- 2083 POSTER Adjuvant delivery of a dose-dense, sequential FEC-docetaxel regimen to patients with high-risk breast cancer is feasible – results of a randomized, open-label Phase II study (2007) (0)
- Abstract PS9-06: Adherence to and patient satisfaction with the combination therapy of exemestane and everolimus in postmenopausal women with HR+ HER2- advanced breast cancer: Results from the IPSOC-mamma study (2021) (0)
- 0139 Why 28% of ER-negative/PR-negative breast cancer (BC) patients did not get chemotherapy (CT) (2009) (0)
- Abstract P2-03-05: Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (ERBB2) mutations in metastatic breast cancer patients (2017) (0)
- 415 Genetic Variability in Multi Drug Resistance Protein 1 (ABCC1/MRP1) and UDP-Glucuronosyltransferase-2B7 (UGT2B7) Are Highly Correlated with Severe Haematological Toxicity of Adjuvant FEC in Breast Cancer (2012) (0)
- Prognostic Significance of Nodal and PgR Status on Early Relapse in Operable HER-2 Positive Breast Cancer from the Pre-Trastuzumab Era (2009) (0)
- REPORT ON TWO CASES SUGGESTING A POSSIBLE ROLE FOR NEOADJUVANT CHEMOTHERAPY AND INTERVAL DEBULKING SURGERY IN THE TREATMENT OF STAGE IV UTERINE PAPILLARY SEROUS CARCINOMA (UPSC) (2004) (0)
- WT1 positivity in endothelial cells surrounding tumoral tissue (2007) (0)
- I.2 From the breast to the uterus. The past and the present (1998) (0)
- Magnetic Seed Localisation for Impalpable Breast Lesions is Preferred over Hooked-Wire (2020) (0)
- HER-1 overexpression is found only in oestrogen receptor negative breast cancer and is rarely associated with HER-1 gene amplification (2007) (0)
- Analysis of miRNA – microarray data of breast cancer for the prediction of lymph node invasion (2010) (0)
- Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer (2022) (0)
- Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials (2023) (0)
- Body mass index and breast cancer survival (2017) (0)
- Abstract PS7-63: Cause of death discordance between death certificates and medical files: Impact on cancer survival assessment in a Belgian case study (2021) (0)
- Chemotherapy-induced peripheral neuropathy: From symptomatology using quantitative sensory testing towards effective treatment (2021) (0)
- Reliability of clinical assessment tools for shoulder dysfunctions in women after breast cancer treatment (2014) (0)
- Authors' reply (1994) (0)
- NCOLOGY aparoscopy-assisted vaginal hysterectomy compared with bdominal hysterectomy in clinical stage I endometrial ancer : safety , recurrence , and long-term outcome (0)
- SECOND CASE OF A UTERINE MESONEPHRIC TUMOR (2004) (0)
- Prognostic effect of tumor size and nodal status across the St. Gallen breast cancer (BC) phenotypes (2013) (0)
- Abstract PD4-04: Effectiveness of myofascial techniques in addition to a standard physical therapy program as postoperative intervention for upper limb pain in breast cancer patients: A randomized controlled trial (2017) (0)
- EP1193 Value of radiotherapy in the management of Paget's disease of the vulva: a retrospective study of 31 patients (2019) (0)
- Abstract P6-14-12: Evaluation of changes in sequencing quality and transcriptomic profiles with increasing post-mortem interval: results from an optimization experiment within the UPTIDER tissue donation program (2023) (0)
- P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes (2023) (0)
- 0183 Progranulin (PC-derived growth factor) levels in serum do not predict response to neoadjuvant capecitabine (X), docetaxel (T) and trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC) (2009) (0)
- Retrospective Cohort Study of Practical Applications of Paramagnetic Seed Localisation in Breast Carcinoma and Other Malignancies (2022) (0)
- Abstract P3-05-40: Association of body mass index with clinicopathological features and survival in patients with primary ER+/HER2- invasive lobular breast cancer (2023) (0)
- WHICH FACTOR DOES PREDICT AXILLARY LYMPH NODE STATUS BEST IN OPERABLE BREAST CANCERS? (2003) (0)
- 63P Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2- high-risk early breast cancer (2022) (0)
- 303P Use of CA 15.3 for the detection of secondary metastatic breast cancer (2020) (0)
- 51P The development of a predictive model for risk results of the 70-gene signature (2021) (0)
- Abstract P3-08-18: Risk of breast-cancer recurrence after a 10-year disease-free interval (2020) (0)
- 60 Comprehensive genome-wide analysis of non-invasive test data allows accurate cancer prediction: a retrospective analysis of over 85.000 pregnancies (2021) (0)
- P52 The axillary lymph node status (ALNS) of breast cancers by combined ER, PR and HER-2 expression: Triple positive tumours are more likely lymph node positive (2007) (0)
- CYPTAM-BRUT 2: A prospective multicenter observational study in the neoadjuvant and metastatic setting investigating tamoxifen response between women with a favorable versus unfavorable endoxifen profile. (2011) (0)
- Assessment of tumor necrosis after neoadjuvant chemotherapy in patients with stage IV endometrial cancer (2008) (0)
- 280 The Expression of RANTES (CCL5) is Inversely Correlated with Lymph Node Involvement in Breast Cancer (2012) (0)
- 333P Ribociclib (RIB) + letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial (2020) (0)
- Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (2020) (0)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2020) (0)
- OC146: Multicenter prospective testing to predict malignancy in adnexal masses using Bayesian network models (2008) (0)
- Improved NPI for breast cancer prognosis (2008) (0)
- Abstract P6-09-32: The association of breast cancer subtype and breast cancer survival with parity and time since last birth (2017) (0)
- Breast Cancer in Pregnancy: Surgical Treatment and Axillary Staging (2011) (0)
- Implication of polysomy 17 in HER-2/neu overexpressing breast cancers (2006) (0)
- The footprint of the aging stroma in older breast cancer patients. (2017) (0)
- Menopausal symptoms and uterine changes in postmenopausal breast cancer patients receiving tamoxifen or third generation aromatase inhibitors (2004) (0)
- Gemcitabine–carboplatin–paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients (2005) (0)
- P325 A Belgian observational study to evaluate fulvestrant use in current clinical practice (2011) (0)
- Étude des interférences Progestins and tamoxifen: interference (2004) (0)
- Low complication rate in the surgical treatment of breast cancer during pregnancy (2011) (0)
- A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer (2021) (0)
- Clinical relevance of plasma matrix metalloproteinase-2 levels in primary invasive breast cancer (2005) (0)
- Mortality and Major Adverse Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy: The First Decade. (2023) (0)
- Withdrawal of exogenous hormones at diagnosis can affect proliferation markers in early luminal breast cancer (2015) (0)
- Different outcome variables yield different results! (2013) (0)
- Abstract P1-07-09: SMAD nuclear staining patterns in inflammatory breast cancer suggest non-canonical TGFβ-signalling establishing collective, sheet-like invasion SMAD nuclear staining patterns in inflammatory breast cancer suggest non-canonical TGFβ-signalling es (2015) (0)
- Abstract P6-07-04: Evaluation of Adjuvant! Online for primary operable grade 2 breast cancers with 10-year follow-up (2012) (0)
- Abstract 1406: Multigene signatures based risk estimates in ER+/HER2- breast cancers: The predictive value of inexpensive statistical models and changes in adjuvant chemotherapy use (2019) (0)
- 0646: Analysis of Her-2/Neu in Recurrent Endometrial Cancer: Limited Clinical Benefit From Trastuzu-Mab (Herceptin°) (2006) (0)
- P54 Triple positive (ER+/PR+/HER-2+) breast carcinomas occur at a younger age than all other ER/PR/HER-2 breast cancer phenotypes (2007) (0)
- Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy (2017) (0)
- Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785]. (2022) (0)
- Abstract P1-10-04: Elacestrant, a novel oral selective estrogen receptor degrader (SERD), decreases tumoral 18F-FES uptake in a phase 1 study of ER+, HER2 -, advanced breast cancer patients (2018) (0)
- Cost-effectiveness analysis of letrozole vs. tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the Belgian perspective (2007) (0)
- Abstract P5-01-05: Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2- advanced/metastatic breast cancer (2020) (0)
- Title: Obesity alters endoxifen plasma levels in young breast cancer patients: A pharmacometric simulation approach. Authors: (2020) (0)
- 1850 Safety of everolimus plus exemestane in elderly patients with Hormone-Receptor-Positive (HR+), HER2- locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors (NSAIs): BALLET (CRAD001YIC04) (2015) (0)
- Measurable Serum Estradiol and Estrone in Women 36-56 Years During Adjuvant Treatment With Aromatase Inhibitors for a Hormone Receptor-Positive Breast Cancer. Case Studies and Cross-sectional Study Using an Ultra-sensitive LC-MS/MS-Method. (2022) (0)
- 00038 POTENTIAL ROLE OF PET-CT IN THE PREOPERATIVE STAGING OF LOCALLY ADVANCED BREAST CANCER (2005) (0)
- P139 Experience with fulvestrant in the endocrine treatment sequence for patients with breast cancer: a Belgian compassionate use programme (2007) (0)
- Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (2020) (0)
- 00037 BREAST CANCER: WHAT ABOUT THE NON-SENTINEL LYMPH NODES IN 85 WOMEN WITH A CT1 BREAST CANCER AND A POSITIVE SENTINEL LYMPH NODE? (2005) (0)
- Mortality and major adverse cardiac events in women with breast cancer receiving radiotherapy: a 10-year cohort study of patients and population controls (2022) (0)
- Analysis of gene expression and methylation data for the identification of novel biomarkers in breast cancer (2013) (0)
- 39OConstitutively activated STAT3 is predictive for trastuzumab resistance in primary HER2 positive breast cancer (2015) (0)
- F04An international multicentre hospital-based retrospective cohort study evaluating the prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients (2016) (0)
- PREDICTING AXILLARY LYMPH NODE STATUS (ALNS) IN WOMEN WITH OPERABLE INVASIVE BREAST CANCER (BC) (2004) (0)
- 342 Prognostic Implications of Invasive Lobular Breast Cancer (2012) (0)
- Circulating estradiol and tumor phenotype in postmenopausal breast cancer patients. (2009) (0)
- Abstract P1-03-05: Genetic variant in the OPG gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients (2015) (0)
- Weight and body mass index (BMI) affect HER-2 expression in postmenopausal breast cancer (2006) (0)
- Age is an independent predictive factor for lymph node metastases in non-pleomorphic lobular carcinoma of the breast but not in the pleomorphic variant (2003) (0)
- Pathologic complete response after neo-adjuvant systemic treatment in breast cancer: Tumour or treatment related? (2014) (0)
- Reply to the Letter to the Editor on "Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients", by I. Cohen Ann Oncol 2005; 16: 1399. (2005) (0)
- 121 A prognostic model for breast cancer-related events in primary operated invasive lobular breast cancers from one centre (2010) (0)
- Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach (2019) (0)
- Abstract PD2-3: High body mass index (BMI) and worse response to neoadjuvant chemotherapy (NACT) by breast cancer phenotype: Own data and external validation on German breast group (GBG) patients (2013) (0)
- HER-2 breast cancer: time from primary diagnosis to metastases by estrogen receptor status (2006) (0)
- 2127 POSTER Activity of Fulvestrant in patients with HER2-positive advanced breast cancer (2007) (0)
- BRCA-1 GENE MUTATION AND A RARE KIND OF CERVICAL CANCER: CHANCE ASSOCIATION OR GENETIC LINK? A CASE REPORT (2003) (0)
- THE IMPACT OF EDUCATIONAL MATERIAL (EM) ON COMPLIANCE AND PERSISTENCE RATES WITH ADJUVANT AROMATASE INHIBITOR (AI) TREATMENT: FIRST YEAR DATA, PRESENTED ON BEHALF OF THE CARIATIDE STUDY INVESTIGATORS (2010) (0)
- Triple receptor comparison between primary breast cancer and metachronous or synchronous liver metastasis (2012) (0)
- Plasma markers showing differential baseline expression in relapsing versus non-relapsing patients with hormone sensitive breast tumors (2020) (0)
- Abstract P2-09-05: 12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer (2017) (0)
- Abstract P6-14-14: Advancing research on metastatic breast cancer: the UPTIDER post-mortem tissue donation program (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Patrick Neven?
Patrick Neven is affiliated with the following schools:
